$0.7276
-0.0377-4.93%
Last update: Nov 12, 5:31 PM
Cardiff Oncology Inc
CRDFNASDAQ
Cardiff Oncology fell 67.5% from $2.24 to $0.73, behind the S&P 500's +10.8%. Its worst day was Jul 15 (−32.1%), and its low came Nov 12 at $0.73.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cardiff Oncology closed at its highest level of the year, 43.3% above where the year started.
+8.1% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with
−32.0% · S&P 500 +0.4%
EPS of $-0.11 beat the $-0.19 estimate on $243,000.00 revenue (est. $114,100.00).
+12.4% · S&P 500 +0.8%
EPS of $-0.18 missed the $-0.13 estimate on $41,000.00 revenue (est. $90,000.00).
−3.5% · S&P 500 −1.2%
Cardiff Oncology shares fell 22.1%, while the S&P 500 rose 0.3%.
−22.1% · S&P 500 +0.3%
Cardiff Oncology shares fell 32.1%, while the S&P 500 rose 0.4%.
−32.1%, the year's worst day, on 13M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-0.14 beat the $-0.16 estimate on $104,000.00 revenue (est. $68,224.00).
−5.7% · S&P 500 +0.3%
Cardiff Oncology shares rose 15.2%, while the S&P 500 fell 0.6%.
+15.2%, the year's best day · S&P 500 −0.6%
EPS of $-0.12 beat the $-0.13 estimate on $171,000.00 revenue (est. $91,144.00).
−4.9% · S&P 500 −0.4%
Where it ended: a close of $0.73 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.13, revenue est. $91,144.00).
Nothing in the past 12 months.
All CRDF dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRDF and SPY from Benzinga historical bars. Not investment advice.
